Ranbaxy, Russian region sign healthcare pact

GURGAON - Ranbaxy Laboratories Limited (Ranbaxy) and The Government of Yaroslavl Region, Russia, today signed a Memorandum of Understanding on cooperation in the field of Healthcare and Medical Science.

The major areas of cooperation are the development of the healthcare system, new medical technologies in the Yaroslavl region, including the expansion of educational programs for the medical and pharmaceutical community, collaboration in the field of clinical trials as well as improvement of drug safety monitoring in medical practice.

As a first step, Ranbaxy will evaluate collaborations with local Academic and Research centers in Yaroslavl region in Russia to broaden the scope of medical educational programs for professional medical and pharmaceutical community. It will also look at cooperation in the area of clinical trials as well as participation in any created clinical trials center.

The Yaroslavl Region in Russia is establishing a pharmaceutical zone and encouraging pharmaceutical companies to set up manufacturing facilities and conduct clinical research.

Commenting on the occasion, Arun Sawhney, Managing Director, Ranbaxy, said, “We are delighted to explore potential opportunities in Yaroslavl to build and strengthen the local pharmaceutical industry.”

Ranbaxy has been present in the Russian pharmaceutical market for around 20 years. The company has registered 51 drugs in the Russian Federation and commercialized 72 SKUs. The company offers products covering therapeutic segments such as antibacterial, gastroenterology, analgesics, cardiovasculars, HIV/AIDS, metabolic disorders etc. Ranbaxy is ranked No. 35 in the Russian retail pharmacy segment among all pharma companies and No 19 in the generic market segment.

Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Ranbaxy’s continued focus on R and D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research.

The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies,” resulting in a number of products under development.

The company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in seven countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan. (ANI)